Mikhael Attias
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
GSK-3 regulates CD4-CD8 cooperation for super-armed CD8+ cytolytic T cells in immunotherapy against tumors.
Journal: Signal transduction and targeted therapy
Published: May 08, 2025
Anti-PD-1 amplifies costimulation in melanoma-infiltrating Th1-like Foxp3+ regulatory T cells to alleviate local immunosuppression.
Journal: Journal for immunotherapy of cancer
Published: November 14, 2024
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
Journal: The Journal of clinical investigation
Published: May 01, 2024
The impact of Foxp3+ regulatory T-cells on CD8+ T-cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors.
Journal: British journal of pharmacology
Published: September 30, 2023
S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas.
Journal: Neoplasia (New York, N.Y.)
Published: November 01, 2022
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
Journal: The Journal of clinical investigation
Published: May 28, 2020
Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma.
Journal: Frontiers in oncology
Published: March 23, 2020
Mechanisms of human FoxP3+ Treg cell development and function in health and disease.
Journal: Clinical and experimental immunology
Published: January 28, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026